Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up36.4% Overall Response Rate (ORR) MaintainedSAN CARLOS, […]